As you might know, Cohance Lifesciences Limited (NSE:COHANCE) recently reported its second-quarter numbers. Revenues of ₹4.8b reported a marginal miss, falling short of forecasts by 2.9%, but earnings were better than expected - statutory profits came in at ₹0.38 per share, a nice change from the loss the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the current consensus from Cohance Lifesciences' nine analysts is for revenues of ₹22.6b in 2027. This would reflect a solid 9.8% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to soar 327% to ₹5.29. Before this earnings report, the analysts had been forecasting revenues of ₹24.6b and earnings per share (EPS) of ₹5.45 in 2027. It's pretty clear that pessimism has reared its head after the latest results, leading to a weaker revenue outlook and a minor downgrade to earnings per share estimates.
See our latest analysis for Cohance Lifesciences
The analysts made no major changes to their price target of ₹512, suggesting the downgrades are not expected to have a long-term impact on Cohance Lifesciences' valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Cohance Lifesciences, with the most bullish analyst valuing it at ₹1,150 and the most bearish at ₹315 per share. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Cohance Lifesciences' growth to accelerate, with the forecast 21% annualised growth to the end of 2027 ranking favourably alongside historical growth of 9.3% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Cohance Lifesciences is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also downgraded Cohance Lifesciences' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Cohance Lifesciences going out to 2029, and you can see them free on our platform here..
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Cohance Lifesciences , and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.